Nasdaq Moves to Delist Lakewood-Amedex After Sub-$1 Bid; Hearing Request Is the Only Stay
LABT sits 36% above its 52-week low of $0.169 on light trading volume (0.3× avg).
Summary
Nasdaq notified Lakewood-Amedex on November 10, 2026 that it intends to delist the stock for trading below $1.00, with no cure period available because of the June 2026 reverse split. A hearing request due November 17 is the only thing preventing a trading suspension at the open on November 19.
Key Events · Legal and Risk Events · LABT
-
Nasdaq Issues Delisting Determination
Staff notified the company on November 10, 2026 that the closing bid was below $1.00 for the 30 business days from September 29 through November 9, 2026, violating Nasdaq Listing Rule 5550(a)(2).
-
No Cure Period Available
Because a 1-for-10 reverse split was effected on June 22, 2026 within the prior year, the company is ineligible for the compliance period under Rule 5810(c)(3)(A)(iv), so Nasdaq moved straight to delisting rather than a cure window.
-
Suspension Deadline and Hearing Stay
Trading would be suspended at the open on November 19, 2026 and a Form 25-NSE filed unless a hearing is requested by November 17, 2026; the company intends to request one, which stays both actions pending the Panel's decision.
-
Remediation Plan May Include Another Reverse Split
The company says it will present a plan to regain compliance with the Bid Price Rule, which may include a reverse stock split, with no assurance the Panel grants continued listing.
Analysis · LABT · Life Sciences
Nasdaq's Staff has opted to delist the company rather than grant a cure period, because the 1-for-10 reverse split executed June 22, 2026 already used up the standard 180-day window under Rule 5810(c)(3)(A)(iv). That removes the usual safety net: the stock's closing bid sat below $1.00 for the 30 business days from September 29 through November 9, 2026, and the only thing standing between the shares and a trading suspension at the open on November 19, 2026 is a hearing request due November 17, 2026. The company says it will file that request, which stays both the suspension and the Form 25-NSE filing until a Hearings Panel rules. The proposed fix is another reverse split, a mechanical share-count reduction that does nothing for the underlying business, which posted a $4.7M first-half net loss with unremediated material weaknesses in internal controls. For a stock at $0.23, a delisting would push trading to the OTC market, thin liquidity further and complicate any future capital raise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LABT was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.17 to $98.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.